Blinatumomab and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL

Soochow University

Status and phase

Enrolling

Phase 1

Conditions

B-cell Acute Lymphoblastic Leukemia

Treatments

Combination Product: blinatumomab and auto-HSCT "sandwich " strategy

Study type

Interventional

Funder types

Other

Identifiers

NCT06507514

SZBALL02

Details and patient eligibility

About

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the main method potentially curing adult B-ALL, but the high treatment-related mortality (NRM) affects overall survival (OS). Autologous stem cell transplantation (auto-HSCT) can significantly reduce NRM but has a higher relapse rate. Studies have confirmed that achieving MRD negativity before Auto-HSCT can effectively reduce post-transplant relapse, achieving similar efficacy to allo-HSCT. The efficacy of blinatumomab in clearing MRD has been confirmed. Therefore, using blinatumomab combined with Auto-HSCT for B-ALL patients seems to make it possible to achieve benefits in leukemia free survival（LFS） and OS. The investigators first conducted blinatumomab and auto-HSCT "sandwich " strategy as consolidation therapy in patients with B-ALL. The main Purpose of this study was to observe the safety and efficacy of this new strategy.

Full description

Enrolled patients received induction chemotherapy with the IVP regimen and two cycles of consolidation chemotherapy: high-dose cytarabine (Ara-c) + pegaspargase (± Tyrosine kinase inhibitors ,TKI) and methotrexate (MTX) + pegaspargase (± TKI). Sequential treatment with blinatumomab was then administered. After the first treatment with blinatumomab, autologous stem cell mobilization and collection were performed. Following successful stem cell collection, autologous stem cell transplantation was conducted. Starting from the third month after autologous stem cell transplantation, the second maintenance treatment with blinatumomab was administered, with one cycle every three months, for a total of four cycles. Long-term follow-up monitoring was then conducted. The follow-up period for this study was two years, and data on two-year LFS, OS, and NRM rates were collected.

Enrollment

4 estimated patients

Sex

All

Ages

15 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

subjects with a primary diagnosis of B-ALL who have any of the following: (a) no suitable allogeneic HSCT donor. (b) refusal of allogeneic HSCT.
positive expression of CD19 in peripheral blood or bone marrow primary cells detected by flow cytometry.
ardiac ultrasound left ventricular ejection fraction ≥ 50%; Creatinine ≤ 1.6 mg/dl; alanine transaminase (ALT) and aspartate aminotransferase (AST) ≤ 3 times the normal range and total bilirubin ≤ 2.0 mg/dl; Pulmonary function ≤ grade 1 dyspnea (CTCAE v5.0) with oxygen saturation > 91% without oxygenation.
subjects aged 15-65 years (including 15 and 65 years), regardless of gender.
T-cell amplification test pass.
expected survival > 3 months.

Exclusion criteria

patients with recurrence of only isolated extramedullary lesions. combination of other malignant tumors.
previously treated with anti-CD19 therapies.
immunosuppressants use within 2 weeks prior to signing informed consent or plan to immunosuppressants after signing informed consent.
uncontrolled active infections.
HIV infection.
active hepatitis B or hepatitis C infection.
history of severe tachyphylaxis to aminoglycoside antibiotics.
history or presence of clinically relevant Central Nervous System (CNS) pathology, such as epilepsy, generalized seizure disorder, paresis, aphasia, stroke, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, or psychosis.